Bell’s Palsy: Diagnosis and Management

JEFFREY D. TIEMSTRA, MD, and NANDINI KHATKHATE, MD
University of Illinois at Chicago College of Medicine, Chicago, Illinois

Bell’s palsy is a peripheral palsy of the facial nerve that results in muscle weakness on one side of the face. Affected patients develop unilateral facial paralysis over one to three days with forehead involvement and no other neurologic abnormalities. Symptoms typically peak in the first week and then gradually resolve over three weeks to three months. Bell’s palsy is more common in patients with diabetes, and although it can affect persons of any age, incidence peaks in the 40s. Bell’s palsy has been traditionally defined as idiopathic; however, one possible etiology is infection with herpes simplex virus type 1. Laboratory evaluation, when indicated by history or risk factors, may include testing for diabetes mellitus and Lyme disease. A common short-term complication of Bell’s palsy is incomplete eyelid closure with resultant dry eye. A less common long-term complication is permanent facial weakness with muscle contractures. Approximately 70 to 80 percent of patients will recover spontaneously; however, treatment with a seven-day course of acyclovir or valacyclovir and a tapering course of prednisone, initiated within three days of the onset of symptoms, is recommended to reduce the time to full recovery and increase the likelihood of complete recuperation. (Am Fam Physician 2007;76:997-1002, 1004. Copyright © 2007 American Academy of Family Physicians.)
Bell's Palsy

A
c

Bell’s Palsy

research has found elevated HSV-1 titers in affected patients. However, studies have failed to isolate viral DNA in biopsy specimens, leaving the causative role of HSV-1 in question.4,5

Many conditions can produce isolated facial nerve palsy identical to Bell’s palsy. Structural lesions in the ear or parotid gland (e.g., cholesteatoma, salivary tumors) can produce facial nerve compression and paralysis. Other causes of peripheral nerve palsies include Guillain-Barré syndrome, Lyme disease, otitis media, Ramsay Hunt syndrome (an outbreak of herpes zoster in the facial nerve distribution), sarcoidosis, and some influenza vaccines. Although these conditions can present as isolated facial nerve palsies, they usually have additional features that distinguish them from Bell’s palsy.

Patients with Lyme disease often have a history of tick exposure, rash, or arthralgias. Facial nerve palsies from acute and chronic otitis media have a more gradual onset, with accompanying ear pain and fever. Patients with Ramsay Hunt syndrome have a pronounced prodrome of pain and often develop a vesicular eruption in the ear canal and pharynx, although cases without the vesicular eruption (i.e., zoster sine herpete) have been reported. Polyneuropathies (e.g., Guillain-Barré syndrome, sarcoidosis) will

![Figure 1. Anatomy of the facial nerve.](image)

**SORT: KEY RECOMMENDATIONS FOR PRACTICE**

<table>
<thead>
<tr>
<th>Clinical recommendation</th>
<th>Evidence rating</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with Bell’s palsy should be treated within three days of the onset of symptoms with a seven-day course of oral acyclovir (Zovirax) or valacyclovir (Valtrex), plus a tapering course of oral prednisone.</td>
<td>B</td>
<td>15-17</td>
</tr>
<tr>
<td>Patients with complete paralysis who do not improve in two weeks on medication should be referred to an otolaryngologist for evaluation for other causes of facial nerve palsy.</td>
<td>C</td>
<td>19, 20</td>
</tr>
<tr>
<td>Patients should be monitored for eye irritation and be prescribed eye lubrication. Patients with corneal abrasions should be referred to an ophthalmologist.</td>
<td>C</td>
<td>1, 23</td>
</tr>
</tbody>
</table>

*A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 922 or http://www.aafp.org/afpsort.xml.
Tumors will present with a more insidious onset of symptoms over weeks or months. Central nervous system lesions (e.g., multiple sclerosis, stroke, tumor) can also cause facial nerve palsy. However, some motor neurons to the forehead cross sides at the level of the brainstem, so the fibers in the facial nerve going to the forehead come from both cerebral hemispheres (Figure 2). Supranuclear (central) lesions affecting the facial nerve will not paralyze the forehead on the affected side, resulting in a unilateral facial paralysis with forehead sparing. Often, there will be at least some weakness of extremities on the affected side as well. Table 1 summarizes the differential diagnosis of Bell’s palsy.

Influenza vaccines in the past have been associated with peripheral neuropathies. Although influenza vaccines currently available in the United States have not been associated with Bell’s palsy, a recently developed Swiss intranasal vaccine was found to have a very high risk of postvaccine facial nerve palsy and has been withdrawn from use. Because influenza vaccines change annually, public health officials should be notified of any cases of Bell’s palsy occurring in the six weeks following vaccine administration.

**Evaluation**

A patient with an acute onset of unilateral facial weakness most likely has Bell’s palsy. A careful history of the onset and progress of paralysis is important because gradual onset of more than two weeks’ duration is strongly suggestive of a mass lesion. Medical history should include recent rashes, arthralgias, or fevers; history of peripheral nerve palsy; exposure to influenza vaccine or new medications; and exposure to ticks or areas where Lyme disease is endemic. The physical examination should include careful inspection of the ear canal, tympanic membrane, and oropharynx, as well as evaluation of peripheral nerve function in the extremities and palpation of the parotid gland. In order to assess forehead involvement, physical examination should also include evaluation of cranial nerve function, including all facial muscles.

Laboratory testing is not usually indicated. However, because diabetes mellitus is pres-
ent in more than 10 percent of patients with Bell’s palsy, fasting glucose or A1C testing may be performed in patients with additional risk factors (e.g., family history, obesity, older than 30 years). Antibiotic therapy may be of benefit; therefore, Lyme antibody titers should be performed if the patient’s history suggests possible exposure. Signs and symptoms atypical for Bell’s palsy should prompt further evaluation. Patients with insidious onset or forehead sparing should undergo imaging of the head. Those with bilateral palsies or those who do not improve within the first two or three weeks after onset of symptoms should be referred to a neurologist.

**Treatment**

**CORTICOSTEROIDS**

Oral corticosteroids have traditionally been prescribed to reduce facial nerve inflammation in patients with Bell’s palsy. Prednisone is typically prescribed in a 10-day tapering course starting at 60 mg per day. A 2004 Cochrane review and meta-analysis of three randomized controlled trials comparing corticosteroids with placebo found small and statistically nonsignificant reductions in the percentage of patients with incomplete recovery after six months (relative risk \( RR = 0.86; 95\% \text{ confidence interval } [CI], 0.47 \text{ to } 1.59 \)) and the percentage of patients with cosmetic complications \( RR = 0.86; 95\% \text{ CI, } 0.38 \text{ to } 1.98 \). However, these trials included only 117 patients; larger prospective trials are needed to establish the benefit of corticosteroids.

**ANTIVIRALS**

Because of the possible role of HSV-1 in the etiology of Bell’s palsy, the antiviral drugs acyclovir (Zovirax) and valacyclovir (Valtrex) have been studied to determine if they have any benefit in treatment. Either acyclovir 400 mg can be given five times per day for seven days or valacyclovir 1 g can be given three times per day for seven days. Although a 2004 Cochrane review found insufficient evidence to support the use of these antivirals alone, recent placebo-controlled trials demonstrated full recovery in a higher percentage of patients treated with an antiviral drug in combination with prednisolone than with prednisolone alone (100 percent versus 91 percent and 95 percent versus 90 percent). However, no benefit was seen when treatment was delayed more than four days after the onset of symptoms (86 percent versus 87 percent).

**SPONTANEOUS RECOVERY**

It is difficult to establish a statistically significant benefit of treatment in placebo-controlled trials because Bell’s palsy has a high rate of spontaneous recovery. The Copenhagen Facial Nerve Study evaluated 2,570 persons with untreated facial nerve palsy, including 1,701 with idiopathic (Bell’s) palsy and 869 with

---

<table>
<thead>
<tr>
<th>Disease</th>
<th>Cause</th>
<th>Distinguishing factors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nuclear (peripheral)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lyme disease</td>
<td>Spirochete <em>Borrelia burgdorferi</em></td>
<td>History of tick exposure, rash, or arthralgias; exposure to areas where Lyme disease is endemic</td>
</tr>
<tr>
<td>Otitis media</td>
<td>Bacterial pathogens</td>
<td>Gradual onset; ear pain, fever, and conductive hearing loss</td>
</tr>
<tr>
<td>Ramsay Hunt syndrome</td>
<td>Herpes zoster virus</td>
<td>Pronounced prodrome of pain; vesicular eruption in ear canal or pharynx</td>
</tr>
<tr>
<td>Sarcoidosis or Guillain-Barré syndrome</td>
<td>Autoimmune response</td>
<td>More often bilateral</td>
</tr>
<tr>
<td>Tumor</td>
<td>Cholesteatoma, parotid gland</td>
<td>Gradual onset</td>
</tr>
<tr>
<td><strong>Supranuclear (central)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple sclerosis</td>
<td>Demyelination</td>
<td>Forehead spared</td>
</tr>
<tr>
<td>Stroke</td>
<td>Ischemia, hemorrhage</td>
<td>Additional neurologic symptoms</td>
</tr>
<tr>
<td>Tumor</td>
<td>Metastases, primary brain</td>
<td>Extremities on affected side often involved</td>
</tr>
</tbody>
</table>

*Information from references 1 and 6 through 8.*
palsy from other causes; 70 percent had complete paralysis. Function returned within three weeks in 85 percent of patients, with 71 percent of these patients recovering full function. Of the 29 percent of patients with sequelae, 12 percent rated it slight, 13 percent rated it mild, and 4 percent rated it severe. Because of these findings, some persons have questioned whether treatment for Bell’s palsy should be routinely indicated; however, patients who have incomplete recovery will have obvious cosmetic sequelae and will often be dissatisfied with their outcome.

Given the safety profile of acyclovir, valacyclovir, and short-course oral corticosteroids, patients who present within three days of the onset of symptoms and who do not have specific contraindications to these medications should be offered combination therapy. Patients who present with complete facial nerve paralysis have a lower rate of spontaneous recovery and may be more likely to benefit from treatment.

**OTHER TREATMENTS**

In the past, surgical decompression within three weeks of onset has been recommended for patients who have persistent loss of function (greater than 90 percent loss on electroneurography) at two weeks. However, the most widely cited study supporting this approach only reported results for a total of 34 treated patients at three different sites, included a nonrandomized control group, and lacked a blinded evaluation of outcome.

The most common complication of surgery is postoperative hearing loss, which affects 3 to 15 percent of patients. Based on the significant potential for harms and the paucity of data supporting benefit, the American Academy of Neurology does not currently recommend surgical decompression for Bell’s palsy.

Some published studies have reported benefit with acupuncture versus steroids and placebo, but all had serious flaws in study design and reporting.

### Table 2. Medications for Treatment of Bell’s Palsy

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dosing</th>
<th>Renal adjustment</th>
<th>Hepatic adjustment</th>
<th>Adverse reactions</th>
<th>Cost*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acyclovir (Zovirax)</td>
<td>Adults: 400 mg five times daily for seven days</td>
<td>Creatinine clearance:</td>
<td>Undefined</td>
<td>Gastrointestinal upset, headache, dizziness, elevated liver enzymes, aplastic anemia (rare)</td>
<td>$66 to $76 (generic) $132 (brand)</td>
</tr>
<tr>
<td></td>
<td>Children older than two years: 80 mg per kg daily divided every six hours for five days, with a maximal dose of 3,200 mg daily</td>
<td>Less than 10 mL per minute (0.17 mL per second): give half dose once daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 to 50 mL per minute (0.17 to 0.83 mL per second): give same dose every 12 to 24 hours</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Valacyclovir (Valtrex)</td>
<td>Adults and children older than 12 years: 1 g three times daily for seven days</td>
<td>Creatinine clearance:</td>
<td>None</td>
<td>Gastrointestinal upset, headache, dizziness, elevated liver enzymes, aplastic anemia (rare)</td>
<td>$208 (brand)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Less than 10 mL per minute: 500 mg daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 to 29 mL per minute (0.17 to 0.48 mL per second): 1 g daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>30 to 49 mL per minute (0.50 to 0.82 mL per second): 1 g twice daily</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednisone or prednisolone</td>
<td>Adults: 60 mg daily for five days, then 40 mg daily for five days</td>
<td>None</td>
<td>Undefined</td>
<td>Headache, nervousness, edema, elevated blood pressure, elevated glucose</td>
<td>$3 (generic) $6 (brand)</td>
</tr>
<tr>
<td></td>
<td>Children: 2 mg per kg daily for seven to 10 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*— Estimated cost to the pharmacist based on average wholesale prices (rounded to the nearest dollar) in Red Book. Montvale, N.J.: Medical Economics Data, 2006. Cost to the patient will be higher, depending on prescription filling fee.
Complications

Patients with Bell’s palsy may be unable to close the eye on the affected side, which can lead to irritation and corneal ulceration. The eye should be lubricated with artificial tears until the facial paralysis resolves. Permanent eyelid weakness may require tarsorrhaphy or implantation of gold weights in the upper lid. Facial asymmetry and muscular contractures may require cosmetic surgical procedures or botulinum toxin (Botox) injections. In these cases, consultation with an ophthalmologist or cosmetic surgeon is needed.22,23

The Authors

JEFFREY D. TIEMSTRA, MD, is an associate professor of clinical family medicine at the University of Illinois at Chicago College of Medicine. He received his medical degree from Rush University in Chicago, and completed a family medicine residency at St. Paul University Hospital in Dallas, Tex.

NANDINI KHATKHATE, MD, is the medical director of the Family Medicine Center and an assistant professor of clinical family medicine at the University of Illinois at Chicago College of Medicine. She received her medical degree from Seth G.S. Medical College in Bombay, India. Dr. Khatkhate completed general practice and neurosurgery residencies in Ayrshire county, Scotland, and a family medicine residency at Cook County Hospital in Chicago.

Address correspondence to Jeffrey D. Tiemstra, MD, Dept. of Family Medicine (MC 663), University of Illinois at Chicago, 1919 W. Taylor St., Chicago, IL 60612 (e-mail: jtiemstr@uic.edu). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES